Literature DB >> 19174584

Ovarian adenocarcinomas in the laying hen and women share similar alterations in p53, ras, and HER-2/neu.

Amy A Hakim1, Catherine P Barry, H John Barnes, Kenneth E Anderson, James Petitte, Regina Whitaker, Jonathan M Lancaster, Robert M Wenham, Donna K Carver, Jane Turbov, Andrew Berchuck, Levy Kopelovich, Gustavo C Rodriguez.   

Abstract

We examined alterations in the p53 tumor suppressor gene and the ras and HER-2/neu oncogenes in chicken ovarian cancers to determine if these tumors have genetic alterations similar to those in human ovarian adenocarcinomas. Mutations in the p53 tumor suppressor gene and the H-ras and K-ras oncogenes were assessed by direct sequencing in 172 ovarian cancers obtained from 4-year-old birds enrolled at age 2 in two separate 2-year chemoprevention trials. Birds in trial B had approximately twice as many lifetime ovulations as those in trial A. Immunohistochemical staining for the HER-2/neu oncogene was done on a subset of avian ovarian and oviductal adenocarcinomas. Alterations in p53 were detected in 48% of chicken ovarian cancers. Incidence of p53 alterations varied according to the number of lifetime ovulations, ranging from 14% in trial A to 96% in trial B (P < 0.01). No mutations were seen in H-ras, and only 2 of 172 (1.2%) tumors had K-ras mutations. Significant HER-2/neu staining was noted in 10 of 19 ovarian adenocarcinomas but in only 1 of 17 oviductal adenocarcinomas. Similar to human ovarian cancers, p53 alterations are common in chicken ovarian adenocarcinomas and correlate with the number of lifetime ovulations. Ras mutations are rare, similar to high-grade human ovarian cancers. HER-2/neu overexpression is common and may represent a marker to exclude an oviductal origin in cancers involving both the ovary and oviduct.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19174584     DOI: 10.1158/1940-6207.CAPR-08-0065

Source DB:  PubMed          Journal:  Cancer Prev Res (Phila)        ISSN: 1940-6215


  33 in total

1.  Measuring the intra-individual variability of the plasma proteome in the chicken model of spontaneous ovarian adenocarcinoma.

Authors:  Adam M Hawkridge; Rebecca B Wysocky; James N Petitte; Kenneth E Anderson; Paul E Mozdziak; Oscar J Fletcher; Jonathan M Horowitz; David C Muddiman
Journal:  Anal Bioanal Chem       Date:  2010-07-17       Impact factor: 4.142

Review 2.  Epithelial ovarian cancer experimental models.

Authors:  E Lengyel; J E Burdette; H A Kenny; D Matei; J Pilrose; P Haluska; K P Nephew; D B Hales; M S Stack
Journal:  Oncogene       Date:  2013-08-12       Impact factor: 9.867

3.  The impact of ovulation on fallopian tube epithelial cells: evaluating three hypotheses connecting ovulation and serous ovarian cancer.

Authors:  Shelby M King; Tyvette S Hilliard; Lucia Y Wu; Randal C Jaffe; Asgerally T Fazleabas; Joanna E Burdette
Journal:  Endocr Relat Cancer       Date:  2011-09-20       Impact factor: 5.678

4.  The use of animal models for cancer chemoprevention drug development.

Authors:  Vernon E Steele; Ronald A Lubet
Journal:  Semin Oncol       Date:  2010-08       Impact factor: 4.929

Review 5.  The chicken model of spontaneous ovarian cancer.

Authors:  Adam M Hawkridge
Journal:  Proteomics Clin Appl       Date:  2014-10       Impact factor: 3.494

6.  In-depth LC-MS/MS analysis of the chicken ovarian cancer proteome reveals conserved and novel differentially regulated proteins in humans.

Authors:  Angelito I Nepomuceno; Huanjie Shao; Kai Jing; Yibao Ma; James N Petitte; Michael O Idowu; David C Muddiman; Xianjun Fang; Adam M Hawkridge
Journal:  Anal Bioanal Chem       Date:  2015-07-10       Impact factor: 4.142

7.  The hen as a model of ovarian cancer.

Authors:  Patricia A Johnson; James R Giles
Journal:  Nat Rev Cancer       Date:  2013-05-16       Impact factor: 60.716

8.  Multi-peptide nLC-PC-IDMS-SRM-based assay for the quantification of biomarkers in the chicken ovarian cancer model.

Authors:  Genna L Andrews Kingon; James N Petitte; David C Muddiman; Adam M Hawkridge
Journal:  Methods       Date:  2013-04-19       Impact factor: 3.608

9.  Selenium-Binding Protein 1 (SBP1) autoantibodies in ovarian disorders and ovarian cancer.

Authors:  Yi Yu-Rice; Seby L Edassery; Nicole Urban; Ingegerd Hellstrom; Karl Erik Hellstrom; Youping Deng; Yan Li; Judith L Luborsky
Journal:  Reproduction       Date:  2016-12-13       Impact factor: 3.906

10.  Influence of C-Trap Ion Accumulation Time on the Detectability of Analytes in IR-MALDESI MSI.

Authors:  Elias P Rosen; Mark T Bokhart; Milad Nazari; David C Muddiman
Journal:  Anal Chem       Date:  2015-10-06       Impact factor: 6.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.